These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 24684301

  • 1. Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice.
    Chiang YT, Ip W, Shao W, Song ZE, Chernoff J, Jin T.
    Endocrinology; 2014 Jun; 155(6):2122-32. PubMed ID: 24684301
    [Abstract] [Full Text] [Related]

  • 2. P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice.
    Chiang YA, Shao W, Xu XX, Chernoff J, Jin T.
    Endocrinology; 2013 Jan; 154(1):77-88. PubMed ID: 23183186
    [Abstract] [Full Text] [Related]

  • 3. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
    Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL.
    Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The rho guanosine 5'-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell.
    Lim GE, Xu M, Sun J, Jin T, Brubaker PL.
    Endocrinology; 2009 Dec; 150(12):5249-61. PubMed ID: 19819966
    [Abstract] [Full Text] [Related]

  • 8. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E, Kim L, Choi JM, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park DI, Park CY.
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
    Giannocco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca-Alaniz MH, Maciel RM, Girardi AC.
    Eur J Pharmacol; 2013 Jan 05; 698(1-3):74-86. PubMed ID: 23051671
    [Abstract] [Full Text] [Related]

  • 12. CD38-mediated Ca(2+) signaling contributes to glucagon-induced hepatic gluconeogenesis.
    Rah SY, Kim UH.
    Sci Rep; 2015 Jun 03; 5():10741. PubMed ID: 26038839
    [Abstract] [Full Text] [Related]

  • 13. The p21-activated kinase 2 (PAK2), but not PAK1, regulates contraction-stimulated skeletal muscle glucose transport.
    Møller LLV, Nielsen IL, Knudsen JR, Andersen NR, Jensen TE, Sylow L, Richter EA.
    Physiol Rep; 2020 Jun 03; 8(12):e14460. PubMed ID: 32597567
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. p21-Activated protein kinases and their emerging roles in glucose homeostasis.
    Chiang YT, Jin T.
    Am J Physiol Endocrinol Metab; 2014 Apr 01; 306(7):E707-22. PubMed ID: 24368667
    [Abstract] [Full Text] [Related]

  • 16. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.
    J Clin Endocrinol Metab; 2006 Nov 01; 91(11):4612-9. PubMed ID: 16912128
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.
    Clin Ther; 2013 Mar 01; 35(3):273-285.e7. PubMed ID: 23433601
    [Abstract] [Full Text] [Related]

  • 19. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H.
    J Am Coll Cardiol; 2012 Jan 17; 59(3):265-76. PubMed ID: 22240132
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.